Cargando…

Allopurinol, Benzbromarone, or a Combination in Treating Patients with Gout: Analysis of a Series of Outpatients

Objective. To profile a sample of gouty patients treated with allopurinol, benzbromarone, or a combination of these two drugs and to describe the impact of this therapy in reducing uric acid levels. Methods. An observational, transversal study was performed. We evaluated 48 patients diagnosed with g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Azevedo, Valderilio Feijó, Buiar, Pedro Grachinski, Giovanella, Laura Helena, Severo, Carolina Rossetti, Carvalho, Mauricio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955622/ https://www.ncbi.nlm.nih.gov/pubmed/24719620 http://dx.doi.org/10.1155/2014/263720

Ejemplares similares

Risk factors and predictors of psoriatic arthritis in patients with psoriasis
por: Azevedo, Valderilio Feijó, et al.
Publicado: (2013)

Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout
por: Kang, Eun Ha, et al.
Publicado: (2021)

Cardiovascular risk associated with allopurinol or benzbromarone treatment in patients with gout
por: Eun, Yeonghee, et al.
Publicado: (2022)

Sex differences in response to allopurinol and benzbromarone in gout: a retrospective cohort study
por: Veenstra, Frouwke, et al.
Publicado: (2021)

Comparison of Benzbromarone and Allopurinol on Primary Prevention of the First Gout Flare in Asymptomatic Hyperuricemia
por: Lai, Shih-Wei, et al.
Publicado: (2022)

Atypical Presentation: Metastatic Uveal Melanoma in a Young Patient without Visual Complaints
por: Buiar, Pedro Grachinski, et al.
Publicado: (2017)

Reduced Incidence of Stroke in Patients with Gout Using Benzbromarone
por: Niu, Sheng-Wen, et al.
Publicado: (2022)

Barriers to the composition and implementation of advance directives in oncology: a literature review
por: Buiar, Pedro Grachinski, et al.
Publicado: (2019)

A Head-To-Head Comparison of Benzbromarone and Allopurinol on the Risk of Type 2 Diabetes Mellitus in People With Asymptomatic Hyperuricemia
por: Lai, Shih-Wei, et al.
Publicado: (2021)

Diabetes and gout: efficacy and safety of febuxostat and allopurinol
por: Becker, M A, et al.
Publicado: (2013)

Hyperuricaemia, gout and allopurinol in the CKD Queensland registry
por: Jeyaruban, A., et al.
Publicado: (2021)

Effect of Clinical Typing on Serum Urate Targets of Benzbromarone in Chinese Gout Patients: A Prospective Cohort Study
por: Xue, Xiaomei, et al.
Publicado: (2022)

The risk of ischemic cerebrovascular disease associated with benzbromarone use in gout people: A retrospective cohort study in Taiwan
por: Lai, Shih-Wei, et al.
Publicado: (2023)

Gout, flares, and allopurinol use: a population-based study
por: Proudman, Charlotte, et al.
Publicado: (2019)

Presence of monosodium urate crystal deposition by dual-energy CT in patients with gout treated with allopurinol
por: Dalbeth, Nicola, et al.
Publicado: (2018)

African American patients with gout: efficacy and safety of febuxostat vs allopurinol
por: Wells, Alvin F, et al.
Publicado: (2012)

Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes
por: Singh, Jasvinder A., et al.
Publicado: (2017)

Transdermal delivery of allopurinol-loaded nanostructured lipid carrier in the treatment of gout
por: Ali, Zakir, et al.
Publicado: (2022)

Cardiovascular safety of febuxostat and allopurinol in patients with gout: A meta-analysis
por: Guan, Xudong, et al.
Publicado: (2022)

Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study
por: Hosoya, Tatsuo, et al.
Publicado: (2020)

Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol
por: Perez-Ruiz, Fernando, et al.
Publicado: (2016)

Benzbromarone, Quercetin, and Folic Acid Inhibit Amylin Aggregation
por: López, Laura C., et al.
Publicado: (2016)

The Effect of Lesinurad in Combination With Allopurinol on Serum Uric Acid Levels in Patients With Gout
por: Baumgartner, Scott, et al.
Publicado: (2018)

Sex difference in heart failure risk associated with febuxostat and allopurinol in gout patients
por: Cheng, Ching-Lan, et al.
Publicado: (2022)

The efficacy and safety of citrate mixture vs sodium bicarbonate on urine alkalization in Chinese primary gout patients with benzbromarone: a prospective, randomized controlled study
por: Xue, Xiaomei, et al.
Publicado: (2020)

Superiority of Low‐Dose Benzbromarone to Low‐Dose Febuxostat in a Prospective, Randomized Comparative Effectiveness Trial in Gout Patients With Renal Uric Acid Underexcretion
por: Yan, Fei, et al.
Publicado: (2022)

Cost-effectiveness of allopurinol versus febuxostat in the treatment of gout patients: A systematic review
por: Rezapour, Aziz, et al.
Publicado: (2020)

Febuxostat versus allopurinol for patients with gout: is it time to overcome concerns regarding cardiovascular safety?
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2021)

Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis
por: Gao, Linggen, et al.
Publicado: (2021)

Updated Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol
por: Pawar, Ajinkya, et al.
Publicado: (2021)

Retraction Note: Transdermal delivery of allopurinol-loaded nanostructured lipid carrier in the treatment of gout
por: Ali, Zakir, et al.
Publicado: (2023)

The EYA Tyrosine Phosphatase Activity Is Pro-Angiogenic and Is Inhibited by Benzbromarone
por: Tadjuidje, Emmanuel, et al.
Publicado: (2012)

Benzbromarone Stabilizes ΔF508 CFTR at the Cell Surface
por: Loo, Tip W., et al.
Publicado: (2011)

Repurposing Benzbromarone for Familial Amyloid Polyneuropathy: A New Transthyretin Tetramer Stabilizer
por: Cotrina, Ellen Y., et al.
Publicado: (2020)

Comment on: “Risk of Erectile Dysfunction in Male Patients with Gout Treated with Febuxostat or Allopurinol: A Propensity Score-Matched Cohort Study”
por: Huang, Jin-Xian, et al.
Publicado: (2023)

Cardiovascular Safety of Febuxostat and Allopurinol in Hyperuricemic Patients With or Without Gout: A Network Meta-Analysis
por: Zhang, Shengzhao, et al.
Publicado: (2021)

Comment on: Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis
por: Deng, Jian‐Hao, et al.
Publicado: (2022)

Hepatic Safety of Febuxostat and Allopurinol for Gout Patients: A Systematic Review of Randomized Controlled Trial
por: Dewi, Christiyanti, et al.
Publicado: (2023)

The Curious Case of Benzbromarone: Insight into Super-Inhibition of Cytochrome P450
por: Parashar, Abhinav, et al.
Publicado: (2014)

Liver failure associated with benzbromarone: A case report and review of the literature
por: Zhang, Ming-Yuan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_dd3vguq1q0j7j3og4vqc5el316